You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 18, 2025

Details for New Drug Application (NDA): 208510


✉ Email this page to a colleague

« Back to Dashboard


NDA 208510 describes VYVANSE, which is a drug marketed by Takeda Pharms Usa and is included in two NDAs. It is available from one supplier. Additional details are available on the VYVANSE profile page.

The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. Twenty suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.
Summary for 208510
Tradename:VYVANSE
Applicant:Takeda Pharms Usa
Ingredient:lisdexamfetamine dimesylate
Patents:0
Pharmacology for NDA: 208510
Physiological EffectCentral Nervous System Stimulation
Medical Subject Heading (MeSH) Categories for 208510
Central Nervous System Stimulants
Dopamine Uptake Inhibitors
Suppliers and Packaging for NDA: 208510
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VYVANSE lisdexamfetamine dimesylate TABLET, CHEWABLE;ORAL 208510 NDA Takeda Pharmaceuticals America, Inc. 59417-115 59417-115-01 100 TABLET, CHEWABLE in 1 BOTTLE (59417-115-01)
VYVANSE lisdexamfetamine dimesylate TABLET, CHEWABLE;ORAL 208510 NDA Takeda Pharmaceuticals America, Inc. 59417-116 59417-116-01 100 TABLET, CHEWABLE in 1 BOTTLE (59417-116-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, CHEWABLE;ORALStrength10MG
Approval Date:Jan 28, 2017TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, CHEWABLE;ORALStrength20MG
Approval Date:Jan 28, 2017TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, CHEWABLE;ORALStrength30MG
Approval Date:Jan 28, 2017TE:ABRLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links